Roivant Short Interest Climbs to a Year High as Earnings Loom

ROIVANT has gained nearly 5% this week, yet the short position against it has grown to its largest in at least a year, a split that puts the stock's November 6 earnings date at the centre of an increasingly charged setup.

Short interest climbed to 5.7% of the free float as of October 20, up roughly 15% over the past month and the highest reading in the 30-day history tracked here. The bulk of that build happened in the second week of October, when the position jumped from around 36.6 million shares to nearly 39.8 million in a matter of days. That is a genuine conviction move rather than a drift, and it happened even as the stock was recovering from its October lows. The context is material: ROIV is up 61% year to date following brepocitinib's approval as the first targeted therapy for adult dermatomyositis, and mosliciguat's strong interim data in pulmonary hypertension. The short build, in other words, is not a response to a fading story. Someone is specifically betting against a stock sitting near its 52-week highs.

The lending market tells a different story from the short interest alone, and the contrast matters. Availability remains extremely loose, with roughly 1,087% of short interest still available to borrow, well above the 52-week trough of 595% recorded on September 21. Borrowing costs have actually eased over the past week, down about 11% to 0.41%, the lowest in the 30-day window. There is no squeeze pressure here. New shorts can be put on cheaply and freely. That makes the position build look like deliberate, low-friction conviction rather than forced repositioning. Options are equally calm: the put/call ratio of 0.80 is almost exactly in line with its 20-day average and nowhere near its 52-week defensive extreme of 1.20. The options market is not adding to the bearish signal from short interest.

The analyst community remains firmly in the other direction. Nine of eleven covering firms rate the stock a buy, with the mean price target at $48.27 against a current price of $34.92, implying roughly 38% notional upside. The cluster of target increases in early September, from Jefferies ($52), TD Cowen ($55), Guggenheim ($46) and Citigroup ($46) among others, followed strong clinical data from mosliciguat. The sole dissent came on October 12, when Wolfe Research downgraded from Outperform to Peer Perform without a stated target, the one recent move that breaks the bullish consensus. The 90-day EPS momentum factor scores in the 76th percentile, reflecting a string of estimate upgrades, while the short score ranks only in the 39th percentile, not an extreme reading. The bear case centres on a history of asset-level failures across batoclimab, IMVT-1402 and others, litigation setbacks, and the concentration of value in assets whose regulatory or commercial trajectories remain binary.

Insider activity over the past 90 days has run to a net negative of roughly $33.7 million in disclosed value, but the composition is worth unpacking. The largest single transaction was a 200,000-share sale on September 30 by Immunovant CEO Eric Venker under a pre-arranged 10b5-1 plan, paired with an exercise of options at $3.85. CEO Matthew Gline and President Mayukh Sukhatme both filed F-code transactions in October, which are tax withholding events on vesting shares, not discretionary sales. There are no open-market P-code purchases in the recent window, but the headline net negative figure is heavily influenced by mechanics rather than conviction selling. Among institutional holders, FMR (Fidelity) added roughly 2.9 million shares in the quarter to September, BlackRock added 4 million, and State Street added 1.6 million. QVT Financial, which had held more than 9% as recently as its last 13G filing, has reduced its disclosed position to 4.3%, below the 5% reporting threshold. That outflow is notable given QVT's prior concentration.

Wikipedia attention spiked to a z-score of 3.3 against the company's own 90-day history in late September, the highest retail attention reading in the dataset. That reading covers the period around the mosliciguat data release and the brepocitinib approval, not the current week, so it reflects the catalyst rather than fresh interest. The closer peer IMVT was essentially flat on the week while ROIV gained 4.7%, and RLAY added 6.3%. The broader mid-cap biotech peer group was mixed to slightly positive, so ROIV's week was good but not an outlier relative to its closest correlates.

The date to watch is November 6, when Roivant reports. The last quarterly print produced a 5% one-day gain and a similar five-day follow-through. Between now and then, the question is whether the short position, which has been built at low cost into a rallying stock, continues to grow, or whether the pace of increase stalls as the stock consolidates near $35.